Antihypertensive drugs and the heart

Current Cardiology Reports

Volumn 6, Issue 6, 2004, Pages 409-415

  Diamond, Joseph A ^a   Phillips, Robert A ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CLONIDINE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; METOPROLOL; MINOXIDIL; OSTEOPONTIN; PRAZOSIN; RAPAMYCIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STROKE; WEIGHT REDUCTION;

EID: 9744259599     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0047-2     Document Type: Review

References (57)

1. Levy D, Anderson KM, Savage D, et al.: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham heart study. Ann Int Med 1988, 108:7-13.
2. Casale PN, Devereux RB, Milner M, et al.: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986, 105:173-178.
3. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322: 561-1566.
4. Bikkina M, Larson MG, Levy D: Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993, 22:1111-1116.
5. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41-46.
6. Cooper RS, Simmons BE, Castaner A, et al.: Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990, 65:441-445.
7. Ghali JK, Liao Y, Simmons B, et al.: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992, 117:831-836.
8. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies [see comments]. JAMA 1996, 275:1507-1513.
9. Muiesan ML, Salvetti M, Rizzoni D, et al.: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995, 13: 091-1095.
10. Bromberg JE, Rinkel GJ, Algra A, et al.: Outcome in familial subarachnoid hemorrhage. Stroke 1995, 26:961-963.
11. Koren MJ, Ulin RJ, Koren AT, et al.: Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002, 15:1021-1028.
12. Schussheim AE, Diamond JA, Phillips RA: Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol 2001, 87:61-65.
13. Sen S, Tarazi RC, Khairallah PA, Bumpus FM: Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974, 35:775-781.
14. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
15. Neaton JD, Grimm RH Jr., Prineas RJ, et al.: Treatment of mild hypertension study: final results. JAMA 1993, 270:713-724.
16. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000, 102:1388-1393.
17. Gottdiener JS, Reda DJ, Massie BM, et al.: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments]. Circulation 1997, 95: 007-2014.
18. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
19. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288: 981-2997.
20. Kupari M, Hautanen A, Lankinen L, et al.: Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998, 97:569-575.
21. Stella P, Bigatti G, Tizzoni L, et al.: Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 2004, 43:265-270.
22. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83: 849-1865.
23. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108: 831-1838.
24. Wilkins BJ, Dai YS, Bueno OF, et al.: Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004, 94: 10-118.
25. Molkentin JD, Lu JR, Antos CL, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
26. Sussman MA, Lim HW, Gude N, et al.: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693.
27. Nagata K, Somura F, Obata K, et al.: AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002, 40:168-174.
28. Collins AR, Schnee J, Wang W, et al.: Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004, 43:1698-1705.
29. Matsui Y, Jia N, Okamoto H, et al.: Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004, 43:1-7.
30. Indolfi C, Di Lorenzo E, Perrino C, et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002, 106:2118-2124.
31. Shioi T, McMullen JR, Tarnavski O, et al.: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
32. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z: In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 2002, 39(2 Pt 2):332-336.
33. Glueck SB, Dzau VJ: Physiological genomics: implications in hypertension research. Hypertension 2002, 39(2 Pt 2 : 10-315.
34. Kimura B, Mohuczy D, Tang X, Phillips MI: Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension 2001, 37(2 Pt 2 : 76-380.
35. Gonzalez-Fernandez RB, Altieri PI, Diaz LM, et al.: Effects of enalapril on heart failure in hypertensive patietns with diastolic dysfunction. Am J Hypertens 1992, 5:480-483.
36. Aronow WS, Kronzon I: Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993, 71:602-604.
37. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [see comments]. Circulation 2000, 102:1388-1393.
38. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
39. Setaro JF, Zaret BL, Schulman DS, et al.: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981-986.
40. Given BD, Lee TH, Stone PH, Dzau VJ: Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. Arch Intern Med 1985, 145:281-285.
41. Hung MJ, Cherng WJ, Kuo LT, Wang CH: Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002, 56: 7-62.
42. Andersson B, Caidahl K, di Lenarda A, et al.: Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996, 94:673-682.
43. Nodari S, Metra M, Dei CL: Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003, 5:621-627.
44. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992, 117:502-510.
45. Gaasch WH: Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction [see comments]. JAMA 1994, 271:1276-1280.
46. Packer M: Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 1990, 81(2 Suppl):III78-III86.
47. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993, 153:154-183.
48. Lorell BH, Isoyama S, Grice WN, et al.: Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood- perfused rabbit hearts. Circ Res 1988, 63:457-467.
49. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [see comments]. N Engl J Med 1997, 336:525-533.
50. Gandhi SK, Powers JC, Nomeir AM, et al.: The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001, 344:17-22.
51. Brutsaert DL, Sys SU, Gillebert TC: Diastolic failure: pathophysiology and therapeutic implications [published erratum appears in J Am Coll Cardiol 1993, 22:1272]. J Am Coll Cardiol 1993, 22:318-325.
52. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560-2571.
53. Hsueh WA, Law RE, Do YS: Integrins, adhesion, and cardiac remodeling. Hypertension 1998, 31(1 Pt 2):176-180.
54. Kuwahara F, Kai H, Tokuda K, et al.: Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004, 43:739-745.
55. Matsumoto T, Wada A, Tsutamoto T, et al.: Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003, 107: 555-2558.
56. Ogata T, Miyauchi T, Sakai S, et al.: Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004, 43:1481-1488.
57. Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Resetting the Hypertension Sails. Hypertension 2003, 41:1178-1179.